55 sec
Rosinbomb | CSL & Arcturus Therapeutics Holdings Inc. Stock Day Media
-
- Investing
Rosinbomb (OTC:ROSN) proudly announces a significant patent filing, showcasing the unique and proprietary air circulation system of the Nature Fresh Freeze Dryer. This innovation includes a revolutionary Piezo electric fan system seamlessly integrated into their innovative honeycomb rack system, optimizing airflow and enabling customers to process nearly twice the amount of material in the same time.
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154. The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response as compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant.
For more information, please visit StockDayMedia.com
Rosinbomb (OTC:ROSN) proudly announces a significant patent filing, showcasing the unique and proprietary air circulation system of the Nature Fresh Freeze Dryer. This innovation includes a revolutionary Piezo electric fan system seamlessly integrated into their innovative honeycomb rack system, optimizing airflow and enabling customers to process nearly twice the amount of material in the same time.
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154. The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response as compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant.
For more information, please visit StockDayMedia.com
55 sec